 |
RheumaShield
by Douglas Labs
30 Capsules
Undenatured Type II Collagen Supplement For Joint Support*
| Our Price: $35.00 | 
|
RheumaShield from Douglas Laboratories contains 10 mg of native, undenatured type II collagen (UC II) from chicken sternum cartilage.*
UC·II is a patented form of undenatured type II collagen. Collagen is a fibrous protein secreted by connective tissue and is the prime structural component of skin, bones and joints. It represents close to 25% of all the body’s protein. Although about 15 types of collagen have
been found in various parts of the body, the fibrillar type II collagen is distributed primarily in articular cartilage, i.e. cartilage associated with joints. UC·II is from cartilage that has been sterilized without substantially altering its chemical or molecular structure. This type of collagen preparation has been shown to maintain the healthy structure and function of articular joints that are damaged by inflammatory conditions such as rheumatoid arthritis, an autoimmune disease.*
Rheumatoid arthritis occurs when one’s own immune system, primarily T cells, attacks itself, i.e. the type II and IX collagen as well as proteoglycans in its articular joint cartilage. The result of this autoimmune attack is painful and disabling inflammation and destruction of
the structure and function of cartilage in articular joints. Rheumatoid arthritis is associated with substantial morbidity and premature mortality from comorbid diseases.*
Studies have shown that oral administration of native, i.e. undenatured, type II collagen significantly improves rheumatoid arthritis, by a mechanism known as oral tolerance. Oral tolerance is a state of anergy or hyporesponsiveness following the exogenous administration of antigen to the peripheral immune system via the gut. Animal studies of experimental autoimmune diseases such as collagen-induced arthritis, insulindependent diabetes, and experimental autoimmune encephalomyelitis have demonstrated effectiveness of oral tolerance.*
The size of the antigen dose determines the mechanism of oral tolerance. In response to a low oral dose of antigen, Peyer’s patches, gut specific lymphoid tissue specialized to respond toantigens entering the body from the intestine, are thought to activate regulatory T-cells to produce inhibitory cytokines, e.g. interleukin 4, interleukin 10 and transforming growth factor beta, and thus reduce the severity of the debilitating tissue inflammation and destruction. Some of the activated T-cells may also migrate to the site of joint inflammation and suppress, via their secreted cytokines, disease inducing T-helper cells (Th1), i.e. bystander suppression. Other studies have also suggested that oral antigen induction of interferon gamma may contribute to oral tolerance by decreasing T-cell migration to peripheral sites of inflammation. High doses of antigen ellicit clonal deletion and anergy.*
A double blind, placebo-controlled study of 60 patients with severe, active rheumatoid arthritis showed that treatment for three months with type II collagen (0.1 to 0.5 mg/d) reduced the number of tender and swollen joints, with no evident side effects and complete remission in four subjects. Another recent double-blind clinical study with a very low dose of type II collagen, 0.25 mg/d, showed an improvement in response rate to treatment. Clinical remission was observed in two of the treatment patients.*
A recent multicenter, double-blind, placebo-controlled trial of 274 rheumatoid arthritis patients tested the efficacy of four doses of type II collagen: 0.020, 0.1, 0.5, and 2.5 mg. Of the 83% of patients completing the 24 week trial, the 0.02 mg group showed a significant increase in
response rate by one of the criteria used. Another placebo-controlled double-blind study of the effect of oral collagen type II upon rheumatoid arthritis showed that 10 mg dose per day of collagen reduced anti-collagen II antibody titer more effectively than a 1 mg/d dose in those with a clinical response. This suggests that antibody titer reduction may be useful in identifying effective responders to oral tolerance treatment.*
RheumaShield is a synergistic combination of UC II in a proprietary blend of Devil’s Claw and Bromelain formulated for optimum joint support.*
|
|
Supplement FactsServing Size: One (1) Capsule
Servings Per Container: 30 | | | | Amount
Per Serving | Daily
Value | Collagen
(UC-II*)
Supplying 10 mg of Undenatured Type II Collagen from Chicken Sternum Cartilage | 40 mg | ** | A Proprietary Blend
(Standardized Devil's Claw Root Extract And Bromelain) | 25 mg | ** | | | * UC-II is a registered trademark of InterHealth Nutraceuticals.UC-II is licensed under U.S. Patents 5,645,581; 5,637,321l; 5,529786 & 5,750,144. |
** Daily Value Not Established. Percent Daily Values are based on a 2,000 calorie diet. |
|
 |
|
|
| Also containsGelatin (Capsule, Potassium Chloride (Stabilizer), Microcrystalline Cellulose and Vegetable Stearate. This product contains NO yeast, wheat gluten, soy protein, milk/dairy, corn, sodium, sugar, starch, artificial coloring, preservatives or flavoring. |
| |
| As a dietary supplement adults take one (1) capsule before bedtime on an empty stomach with Eight (8) Ounces of water, or as directed by a physician. |
| |
| Store in a cool, dry place, away from direct light.KEEP OUT OF REACH OF CHILDREN. |
| |
| This product contains NO yeast, wheat gluten, soy protein, milk/dairy, corn, sodium, sugar, starch, artificial coloring, preservatives or flavoring. |
|
|
|
| Inflammation Nutrition, Joint Comfort, Joint Health, Joint Mobility, Joint Pain |
| |
| Connective Tissue, Joints, Tissue |
| |
Barnett ML, Kremer JM, St Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998;41:290-7.
Cazzola M, Antivalle M, Sarzi-Puttini P, et al. Oral type II collagen in the treatment of rheumatoid arthritis. A six-month double blind placebo- controlled study. Clin Exp Rheumatol 2000;18:571-578.
Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 1999;73:153-264.
Fowler E, Weiner HL. Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases. Biopolymers
1997;43:323-35.
Garcia G, Komagata Y, Slavin AJ, et al. Suppression of collageninduced arthritis by oral or nasal administration of type II collagen. J Autoimmun 1999;13:315-24.
Gimsa U, Sieper J, Braun J, et al. Type II collagen serology: a guide to clinical responsiveness to oral tolerance? Rheumatol Int
1997;16:237-40.
Gonnella PA, Chen Y, Inobe J, et al. In situ immune response in gut-associated lymphoid tissue (GALT) following oral antigen in TCR- transgenic mice. J Immunol 1998;160:4708-18.
Hauselmann HJ, Caravatti M, Seifert B, et al. Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long- standing rheumatoid arthritis? A double-blind, randomized trial. Br J Rheumatol 1998;37:1110-7.
Kagnoff MF. Oral tolerance: mechanisms and possible role in inflammatory joint diseases. Baillieres Clin Rheumatol 1996;10:41-54.
Koh DR. Oral tolerance: mechanisms and therapy of autoimmune diseases. Ann Acad Med Singapore 1998;27:47-53.
Kojima T, Mwale F, Yasuda T, et al. Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. Arthritis Rheum 2001;44:120-127.
Lee HO, Miller SD, Hurst SD, et al. Interferon gamma induction during oral tolerance reduces T-cell migration to sites of inflammation. Gastroenterology 2000;119:129-138.
Marth T, Ring S, Schulte D, et al. Antigen-induced mucosal T cell activation is followed by Th1 T cell suppression in continuously fed ovalbumin TCR-transgenic mice. Eur J Immunol 2000;30:3478-3486.
McKown KM, Carbone LD, Bustillo J, et al. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 2000;43:1054-61.
Meyer O. Oral immunomodulation therapy in rheumatoid arthritis. Joint Bone Spine 2000;67:384-92.
Mitchison A, Sieper J. Immunological basis of oral tolerance. Z Rheumatol 1995;54:141-4.
Nagler-Anderson C. Tolerance and immunity in the intestinal immune system. Crit Rev Immunol 2000;20:103-120.
Peng HJ, Chang ZN, Kuo SW, et al. Resting B cells are not antigen-presenting cells in the induction of oral tolerance of specific Th2 immune responses in mice. Int Arch Allergy Immunol 2000;122:174-181.
Sieper J, Kary S, Sorensen H, et al. Oral type II collagen treatment in early rheumatoid arthritis. A double- blind, placebo-controlled, randomized trial. Arthritis Rheum 1996;39:41-51.
Smith KM, Eaton AD, Finlayson LM, et al. Oral tolerance. Am J Respir Crit Care Med 2000;162:S175-S178.
Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993;261:1727-30.
Weiner HL. Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 1997;48:341-51.
Weiner HL. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J Clin Invest 2000;106:935-7. |
| |
| http://securepics.org/__images/DouglasLabs/_labels/ResistanceSupportFormula_DL8110084X_LABEL.png |
|
 |
Our Price: $35.00 |
|
|
|
|
